<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726528</url>
  </required_header>
  <id_info>
    <org_study_id>17-078</org_study_id>
    <nct_id>NCT03726528</nct_id>
  </id_info>
  <brief_title>Optimized Characterization of Takotsubo Syndrome by Obtaining Pressure Volume Loops</brief_title>
  <acronym>OCTOPUS</acronym>
  <official_title>Optimized Characterization of Takotsubo Syndrome by Obtaining Pressure Volume Loops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this prospective study is to assess the pathophysiology of Takotsubo Syndrome by
      obtaining pressure volume loops with conductance catheters, which allows detailed conclusions
      regarding systolic and diastolic hemondynamics and subsequently regarding potential
      underlying mechanisms
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>systolic/diastolic pressure-volume relationship (mmHg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>peak-power index (mmHG/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>peak filling rate (ml/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>stroke work (mmHG x ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>relaxation constant &quot;Tau&quot; (ms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>time to Emax (ms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in contractility derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>max/min rate of left ventricular pressure change (mmHg/s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energetic parameters derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>stroke work, potential energy (mmHg x ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energetic parameters derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>total pressure volume area (mmHg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Afterload parameters derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>arterial elastance (mmHg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Afterload parameters derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>ventricular arterial coupling (no dimension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Afterload parameters derived from pressure-volume measurements</measure>
    <time_frame>Day 0</time_frame>
    <description>total arterial compliance (mmHg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Correlation of pressure-volume measurements with morphological and functional findings in CMR imaging</measure>
    <time_frame>Day 3</time_frame>
    <description>(presence of myocardial edema or late gadolinium enhancement, native T1 time, myocardial strain assessed by CMR feature tracking)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Correlation of pressure-volume measurements with biomarker release</measure>
    <time_frame>Day 0</time_frame>
    <description>(troponin, NT-proBNP)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Takotsubo Syndrome</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurements of left ventricular pressure and volume</intervention_name>
    <description>Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed Takotsubo syndrome according to current diagnostic criteria including
             complete normalization of left ventricular function during follow-up

          -  Sinus rhythm during invasive measurements

          -  Age â‰¥18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Signs of myocarditis or myocardial infarction with spontaneous lysis of thrombus in
             cardiac magnetic resonance imaging

          -  Pregnancy

          -  Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ingo Eitel, MD</last_name>
    <phone>+49 451 500 44501</phone>
    <email>ingo.eitel@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Stiermaier, MD</last_name>
    <phone>+49 451 500 44501</phone>
    <email>thomas.stiermaier@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical clinic II-UKSH</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingo Eitel, MD</last_name>
      <phone>+49 451 500 44501</phone>
      <email>ingo.eitel@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Stiermaier, MD</last_name>
      <phone>+49 451 500 44501</phone>
      <email>thomas.stiermaier@uksh.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Ingo Eitel</investigator_full_name>
    <investigator_title>MD, Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

